Page last updated: 2024-12-04

3-deazaadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-deazaadenosine: RN given refers to parent cpd. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23190
CHEMBL ID202701
SCHEMBL ID1738519
MeSH IDM0069602
PubMed CID1651
CHEMBL ID17777
SCHEMBL ID20418948
SCHEMBL ID17780621
MeSH IDM0069602

Synonyms (63)

Synonym
BIDD:GT0703
deaza-ado
3-deazaadenosine
6736-58-9
3dza
(2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
{1h-imidazo[4,5-c]pyridine,} 4-amino-1-.beta.-d-ribofuranosyl-
dhcda
3-deazaadenosine, 3-deazaa
c^3ado
3-deaza-adenosine
AD3 ,
1HP0
DB04546
1-(beta-d-ribofuranosyl)-1h-imidazo[4,5-c]pyridin-4-amine
(2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
CHEMBL202701
9-deazaado
cas_6736-58-9
bdbm82055
037v4520iy ,
unii-037v4520iy
nsc 167897
1h-imidazo(4,5-c)pyridine, 4-amino-1-beta-d-ribofuranosyl-
1h-imidazo(4,5-c)pyridin-4-amine, 1-beta-d-ribofuranosyl-
1h-imidazo(4,5-c)pyridin-4-amine, 1-.beta.-d-ribofuranosyl
3-deaza adenosine
gtpl5115
(2r,3r,4s,5r)-2-{4-amino-1h-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)oxolane-3,4-diol
SCHEMBL1738519
(2r,3r,4s,5r)-2-(4-amino-1h-imidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
J-700350
AKOS024260271
AC-32285
DTXSID2040941
HY-W013332
CS-W014048
1-beta-d-ribofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine
Q27073728
NCGC00093846-07
(2r,3r,4s,5r)-2-(4-amino-1h-imidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol hydrochloride;1-(beta-d-ribofuranosyl)-1h-imidazo[4,5-c]pyridin-4-amine hydrochloride
A852357
AS-78389
PD019530
adenosine, 3-deaza-
1h-imidazo[4, 1-.beta.-d-ribofuranosyl-
mls003106659 ,
nsc-167897
nsc167897
1h-imidazo[4, 4-amino-1-.beta.-d-ribofuranosyl-
3dado
smr001821551
1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine
FT-0665514
2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
CHEMBL17777
1-.beta.-d-arabinofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine
DBZQFUNLCALWDY-UHFFFAOYSA-N
SCHEMBL20418948
SCHEMBL17780621
deae-cellulose, (approx. 70per cent moisture content)
DTXSID70859986
PD066520

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Nitric oxide (NO) bioavailability was detected by a NO probe."( Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells.
Kumar, M; Moshal, KS; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" In normal cultures (without myasthenic serum), 3DZA inhibited AChR degradation with a broad dose-response relationship, beginning as low as 2 microM (P < ."( 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
Adams, R; Drachman, DB; Kuncl, RW; Lehar, M, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency6.55630.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency8.91250.00018.4406100.0000AID720579; AID720580
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, INOSINE-ADENOSINE-GUANOSINE-PREFERRING NUCLEOSIDE HYDROLASETrypanosoma vivaxKi0.20000.20000.20000.2000AID977610
Adenosine receptor A3Homo sapiens (human)Ki0.46100.00000.930610.0000AID1802102
AdenosylhomocysteinaseHomo sapiens (human)IC50 (µMol)4.69500.00152.11118.7000AID1862790; AID199925
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki61.70000.00030.91969.0000AID33337
Adenosine receptor A2aHomo sapiens (human)Ki0.46100.00001.06099.7920AID1802102
Adenosine receptor A1Homo sapiens (human)Ki0.46100.00020.931610.0000AID1802102
Adenosine deaminase Bos taurus (cattle)Ki360.00000.00000.48937.0000AID33657; AID33677
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (103)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
one-carbon metabolic processAdenosylhomocysteinaseHomo sapiens (human)
S-adenosylmethionine cycleAdenosylhomocysteinaseHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
adenosylhomocysteinase activityAdenosylhomocysteinaseHomo sapiens (human)
protein bindingAdenosylhomocysteinaseHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
nucleusAdenosylhomocysteinaseHomo sapiens (human)
endoplasmic reticulumAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
melanosomeAdenosylhomocysteinaseHomo sapiens (human)
extracellular exosomeAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay IDTitleYearJournalArticle
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID108463Compound was tested for antiviral activity against measles virus in vero cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID224916Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID216407Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells vesicular stomatitis virus (VSV)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID64120Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID33677Inhibition of calf intestinal adenosine deaminase1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
AID207136Compound was tested for inhibition of human sternal marrow cell (D98) growth at a concentration of 100 uM1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents.
AID1862795Cytotoxicity against human L02 cells assessed as cell growth inhibition2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID226341Antiviral activity against sindbis virus in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID229026Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1862792Cytotoxicity against human A549 cells assessed as cell growth inhibition2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID199175Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells reovirus type 11984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID85567Concentration required to inhibit HSV type 1 strain 377 induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID83887Compound was tested for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID68253Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID68255Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID138987In vitro antiviral activity against herpes simplex virus type 1 (strain E-377) grown in mouse fibroblasts cells, clone L-929, expressed as virus ration (VR)1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target.
AID261568Antitrypanosomal activity against Trypanosoma brucei2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Antitrypanosomal activity of 5'-deoxy-5'-(iodomethylene)adenosine and related 6-N-cyclopropyladenosine analogues.
AID54505Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells coxsackie virus type 41984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID155643Percentage of apoptotic cells in human peripheral blood mononuclear cells after 72 hour incubation at the concentration 1 uM1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Modulation of apoptosis in human lymphocytes by adenosine analogues.
AID1636906Inhibition of DOT1L (unknown origin) at 200 uM using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method2016Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
AID217966In vitro for antiviral activity in secondary cultures of rabbit kidney cells infected with vaccinia virus1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID216409Compound was tested for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1862788Inhibition of SAH hydrolase (unknown origin) at 25 uM2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID63948Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID229236Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID199925Inhibitory activity against S-adenosyl-homocysteine hydrolase1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
1-beta-D-arabinofuranosyl-1H-imidazo[4,5-c]pyridine (ara-3-deazaadenine).
AID1862794Cytotoxicity against human MGC-803 cells assessed as cell growth inhibition2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID1862793Cytotoxicity against human HeLa cells assessed as cell growth inhibition2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID1862790Inhibition of SAH hydrolase (unknown origin)2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID33657Binding affinity against calf intestine adenosine deaminase enzyme1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
AID155645Percentage of apoptotic cells in human peripheral blood mononuclear cells after 72 hour incubation at the concentration 30 uM1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Modulation of apoptosis in human lymphocytes by adenosine analogues.
AID155644Percentage of apoptotic cells in human peripheral blood mononuclear cells after 72 hour incubation at the concentration 10 uM1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Modulation of apoptosis in human lymphocytes by adenosine analogues.
AID1862789Inhibition of SAH hydrolase (unknown origin) at 5 uM2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID79419Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control. 1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
(+/-)-3-(4-Amino-1H-pyrrolo[2,3-d]pyrimidin-1-yl)-5-(hydroxymethyl)- (1 alpha,2 alpha,3 beta,5 beta)-1,2-cyclopentanediol, the carbocyclic analogue of tubercidin.
AID1245164Cytotoxicity against human SKBR3 cells2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.
AID64121Tested for minimum inhibitory concentration against vesicular stomatitis virus (VSV) in E6SM cells1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID225768Antiviral activity against polio virus type 1 in HeLa cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID162252Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells polio virus type 11984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID139845Compound was tested for inhibition of mouse connective tissue cell (L) growth at a concentration of 100 uM1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents.
AID67457Inhibition of lymphocyte-mediated cytolysis at a concentration of 100 uM in [51Cr]- labelled EL4 leukemia cells1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents.
AID204960Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells sindbis virus1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID85279Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1245163Cytotoxicity against human MDA-MB-231 cells2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.
AID85701In vitro antiviral activity in secondary cultures of rabbit kidney cells infected with HSV type 1 strain 3771984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID33337Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID228408Antiviral activity against reovirus type 1 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1245162Cytotoxicity against human MCF7 cells2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.
AID68254Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID217996Compound was tested for antiviral activity against vaccinia virus in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID229234Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines,1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID68256Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID1862791Cytotoxicity against human MCF7 cells assessed as cell growth inhibition2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Synthesis and biological evaluation of novel pentanediamide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors.
AID84957Compound was tested for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID68257Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID220033Antiviral activity against coxsackie B4 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID64118Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID68252Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID54507Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells coxsackie virus type B41984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID217834Concentration required to inhibit vaccinia virus induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID176933Dose required to produce an acute inflammatory response of the algal poly saccharide carrageenan into the pleural cavity of rat.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents.
AID84402Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID220034Antiviral activity against coxsackie B4 virus in HeLa cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID228985Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID155782Percentage of apoptotic cells in human peripheral blood mononuclear cells after 72 hour incubation at the concentration 60 uM1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Modulation of apoptosis in human lymphocytes by adenosine analogues.
AID155599Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells parainfluenza virus type 31984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Apr-13, Volume: 307, Issue:5
Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Apr-13, Volume: 307, Issue:5
Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax.
AID1802102Radioligand Binding Assay from Article 10.1021/acschembio.6b00357: \\Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists\\2016ACS chemical biology, 10-21, Volume: 11, Issue:10
Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID493017Wombat Data for BeliefDocking1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (228)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990110 (48.25)18.7374
1990's58 (25.44)18.2507
2000's40 (17.54)29.6817
2010's9 (3.95)24.3611
2020's11 (4.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.22 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.44%)5.53%
Trials0 (0.00%)5.53%
Reviews3 (1.33%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.44%)0.25%
Observational0 (0.00%)0.25%
Other221 (97.79%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]